San Diego-based Dexcom plans to highlight the benefits of its continuous glucose monitor (CGM) biosensor technology for people with all types of diabetes across the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona this week.
The company says that new registry data demonstrates that long-term use of the Dexcom G7 CGM supports weight management and lowers A1C for people with type 2 diabetes who aren’t on insulin therapy. Analysts recently said that this population could offer a growth catalyst for Dexcom in the coming years.
Additionally, Dexcom plans to share upcoming product features across its portfolio at ATTD. It also intends to present the first consensus-based CGM competency framework to deliver confident, consistent CGM support.
The company says its presence at ATTD builds on the recent rollout of its G7 15 Day CGM, which is now fully available in the U.S.
“There is no better global stage than ATTD to showcase how we’re shaping the future of glucose biosensing around the world. This year’s conference is especially meaningful for me as it marks my first major diabetes industry event as CEO,” said Jake Leach, president and CEO at Dexcom. “The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with type 2 diabetes, including those not using insulin. That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.”
More on Dexcom’s presence at ATTD 2026
Dexcom plans to present several abstracts demonstrating how its CGMs can help improve long-term health and reduce hospitalizations across diabetes types.
Findings include one-year real-world impact data on Dexcom CGM on HbA1C in non-insulin-treated type 2 diabetes from U.S. primary care evidence. This registry showed that, after one year of use, people in this population saw significant improvement in A1C and weight management.
Claims data also highlighted the association of CGM initiation with reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits in those with type 1 diabetes.
Additionally, a feasibility study supported the use of Smart Basal, the company’s new basal insulin dosing optimizer. It demonstrated safety and efficacy of the optimizer for people with type 2 diabetes starting or optimizing basal insulin therapy.
The company also plans to highlight its near-term product portfolio, including the G7 offerings, Dexcom ONE+ and Stelo. It also plans to update on its G8 next-generation sensor.
Leach outlined the company’s roadmap in an interview with Drug Delivery Business News in January.
